

# **INSPIREMD, INC.**

FORM	8-K
(Current repo	rt filing)

# Filed 06/05/12 for the Period Ending 06/01/12

Telephone(888) 776-6804CIK0001433607SymbolNSPRSIC Code3841 - Surgical and Medical Instruments and ApparatusIndustryMedical Equipment, Supplies & DistributionSectorHealthcareFiscal Year12/31

Powered By EDGAR Online

http://www.edgar-online.com

© Copyright 2020, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use.

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

### FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 1, 2012

### **InspireMD**, Inc.

(Exact Name of Registrant as Specified in Charter)

000-54335

Delaware (State or other jurisdiction of incorporation)

(Commission File Number)

26-2123838 (IRS Employer Identification No.)

4 Menorat Hamaor St. Tel Aviv, Israel

(Address of principal executive offices)

67448 (Zip Code)

Registrant's telephone number, including area code: 972-3-691-7691

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

□ Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))

## Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On June 1, 2012, Asher Holzer, Ph.D., director and president of InspireMD, Inc. (the "*Company*"), resigned as the Company's president in connection with Dr. Holzer's retirement as an officer of the Company, effective June 1, 2012. Dr. Holzer remains on the Company's board of directors. In connection with Dr. Holzer's resignation, the Company and Dr. Holzer entered into a Consulting Agreement (the "*Consulting Agreement*"), pursuant to which, among other things, Dr. Holzer agreed to provide the Company with consulting services for a period of six months, terminating on November 30, 2012, in exchange for payments by the Company of NIS 79,783 per month, plus applicable VAT.

On June 1, 2012, Dr. Holzer, OSH-IL, the Israeli Society of Occupational Health and Safety Ltd., Company No. 513308247 (" **OSHIL** "), a company controlled by Dr. Holzer, and InspireMD Ltd., the Company's wholly owned subsidiary, entered into a Separation Agreement and Release (the " **Separation Agreement** "), pursuant to which, among other things, that certain Consultancy Agreement, dated as of April 29, 2012, by and between InspireMD Ltd. and OSHIL was terminated and Dr. Holzer resigned as president of InspireMD Ltd. and as a director of InspireMD Ltd.

The Consulting Agreement and the Separation Agreement are attached as Exhibits 10.1 and 10.2 to this Current Report on Form 8-K. The above descriptions are qualified by reference to the complete text of the documents and agreements described.

#### Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On June 1, 2012, the Company's board of directors approved a change in the Company's fiscal year-end from December 31 to June 30, effective June 30, 2012. The Company plans to report its financial results for the six month transition period of January 1, 2012 through June 30, 2012 on an Annual Report on Form 10-K/T and to thereafter file reports for each twelve month period ended June 30 of each year beginning with the twelve month period ended June 30, 2013.

2

#### Item 8.01 Other Events.

On June 5, 2012, the Company issued a press release announcing the retirement of Dr. Holzer as president of the Company.

#### Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description	
10.1	Consulting Agreement, dated as of June 1, 2012, by and between InspireMD, Inc. and Asher Holzer, Ph.D.	
10.2	Separation Agreement and Release, made as of June 1, 2012, by and between InspireMD Ltd., OSH-IL, the Israeli Society of Occupational Health and Safety Ltd., Company No. 513308247 and Asher Holzer, Ph.D.	
99.1	Press release dated June 5, 2012.	
	3	

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### **INSPIREMD, INC.**

Date: June 5, 2012

By: /s/ Craig Shore

Name: Craig Shore Title: Chief Financial Officer

E	Exhibit Number Description		
	10.1	Consulting Agreement, dated as of June 1, 2012, by and between InspireMD, Inc. and Asher Holzer, Ph.D.	
	10.2	Separation Agreement and Release, made as of June 1, 2012, by and between InspireMD Ltd., OSH-IL, the Israeli Society of Occupational Health and Safety Ltd., Company No. 513308247 and Asher Holzer, Ph.D.	
	99.1	Press release dated June 5, 2012.	

#### CONSULTING AGREEMENT

This Consulting Agreement ("*Agreement*") is by and between InspireMD, Inc., a Delaware corporation (the "*Company*"), and Asher Holzer, Ph.D. ("*Consultant*"). This Agreement is entered into as of June 1, 2012 ("*Effective Date*"). The parties agree to this Agreement as follows:

#### RECITALS

The Company wishes to utilize certain services which can be performed by Consultant, and Consultant can provide and desires to render to the Company such services, and the parties agree that it would be to their mutual advantage to execute this Agreement and thereby define the terms and conditions which shall control the rendering of services provided to the Company by Consultant. This Agreement does not purport to set forth all of the terms and conditions of the services provided to the Company by Consultant.

In consideration of the promises and mutual covenants in this Agreement, the Company and Consultant agree as follows:

#### I. SERVICES TO BE PROVIDED BY CONSULTANT

A. <u>Description of Consulting Services</u>. Subject to the terms of this Agreement, the Company retains Consultant, and Consultant agrees with the Company, to serve as a consultant to the Company for the purpose of providing the Company with such general business advice as the Company's chief executive officer may request, including, without limitation, providing advice regarding business development, financing strategies and product development strategy (collectively, the services to be performed by Consultant shall be the " *Consulting Services*"). It is agreed that other consulting services may be undertaken that are outside the foregoing scope of these services by mutual consent.

**B.** <u>Company's Reliance</u>. The Company is entering into this Agreement in reliance on Consultant's special and unique abilities in rendering the Consulting Services and Consultant will use Consultant's best effort, skill, judgment, and ability in rendering the Consulting Services.

C. <u>Representations by Consultant</u>. Consultant represents to the Company that Consultant is under no contractual, legal or fiduciary obligation or burden that reasonably may be expected to interfere with Consultant's ability to perform the Consulting Services in accordance with the Agreement's terms, including without limitation any agreement or obligation to or with any other company, and that Consultant is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of Consultant's engagement by the Company or to refrain from competing, directly or indirectly, with the business of any other party. Consultant agrees that Consultant will not use, distribute or provide to anyone at the Company any confidential or proprietary information belonging to any other company or entity, at any time during Consultant's performance under this Agreement. Consultant further represents that Consultant's performance of the Consulting Services will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by Consultant in confidence or in trust prior this Agreement, and Consultant will not disclose to the Company or induce the Company to use any confidential or proprietary information belonging to use any confidential or proprietary information to use any confidential or proprietary information proprietary information to use any confidential or proprietary information to the company to use any confidential or proprietary information proprietary to use any confidential or proprietary information or material belonging to any other party.

**D.** <u>Nature of Relationship Between Parties</u>. Consultant will render the Consulting Services in this Agreement as an independent contractor, while specifically adhering to the rules, policies, regulations and procedures of the Company, as may be amended by the Company at anytime. Except as otherwise specifically agreed to by the Company in writing, Consultant shall have no authority or power to bind the Company with respect to third parties and Consultant shall not represent to third parties that Consultant has authority or power to bind the Company. It is not the intention of the parties to this Agreement to create, by virtue of this Agreement, any employment relationship, trust, partnership, or joint venture between Consultant and the Company or any of its affiliates, except as specifically provided in this Agreement, to make them legal representatives or agents of each other or to create any fiduciary relationship or additional contractual relationship among them.

#### II. COMPENSATION FOR CONSULTING SERVICES

A. <u>Consulting Fee</u>. The Company shall pay Consultant for the Consulting Services rendered hereunder NIS 79,783 per month, plus applicable VAT, payable on the last business day of each calendar month, commencing on June 29, 2012. The payments provided for in this Section are collectively referred to as the "*Consulting Fee*". The Consulting Fee constitutes the sole compensation to which Consultant will be entitled for performance of the Consulting Services.

**B.** Expense Reimbursement. The Company shall reimburse Consultant for all reasonable business expenses Consultant incurs in performing the Consulting Services, provided that Consultant receives prior written approval from the Company and the expenses are in compliance with the Company's travel and expense policies. Consultant shall submit all appropriate and supporting documentation for expense reimbursement. Reimbursement will be made in accordance with the Company's expense reimbursement policies.

C. <u>Benefits</u>. Consultant shall at all times be an independent contractor (and not an employee or agent of the Company); therefore, Consultant, by virtue of this Agreement, shall not be entitled to participate in any benefit plans or programs that the Company provides or may provide to its employees, including, but not limited to, pension, profit-sharing, medical, dental, workers' compensation, occupational injury, life insurance and vacation or sick benefits; <u>provided</u>, <u>however</u>, that so long as Consultant remains a director of the Company, Consultant shall be eligible to participate in any benefit plans or programs that the Company provides or may provide to its directors.

**D.** <u>Workers' Compensation</u>. Consultant understands and acknowledges that the Company shall not obtain workers' compensation insurance covering Consultant.

#### III. PAYMENT OF TAXES

A. <u>Foreign, Federal, State, and Local Taxes</u>. No foreign, federal, state, or local income tax or payroll tax of any kind shall be withheld or paid by the Company on behalf of Consultant. Consultant shall not be treated as an employee of the Company with respect to services performed under the Agreement for foreign, federal, state, or local tax purposes.

**B.** <u>Notices to Contractor About Tax Duties And Liabilities</u>. Consultant understands that Consultant is responsible to pay, according to the applicable law, Consultant's income taxes. The parties agree that any tax consequences or liability arising from the Company's payments to Consultant shall be the sole responsibility of Consultant. Should any state or federal or local taxing authority determine that any of the payments under Section II(A) constitute income subject to withholding under any foreign, federal or state or local law, then Consultant agrees to indemnify and hold the Company harmless for any and all tax liability, including, but not limited to, taxes, levies, assessments, fines, interest, costs, expenses, penalties, and attorneys' fees.</u>

#### IV. INDEMNIFICATIONS AND COVENANTS

A. Limitations on the Company's Liability and Consultant's Indemnification of the Company. By entering into this Agreement and receiving the Consulting Services, but subject to the other Agreement terms, the Company will not be liable for any Damages (defined below) caused by Consultant's dishonesty, willful misconduct, or gross negligence or for Consultant's breach of this Agreement. Consultant shall indemnify and hold harmless the Company from and against all losses, judgments, damages, expenses (including, without limitation, reasonable fees and expenses of counsel), liabilities, judgments, and amounts paid in settlement (collectively "Damages") incurred by or asserted against the Company arising from, as a result of, in connection with, or relating to Consultant's dishonesty, willful misconduct, or gross negligence in performing this Agreement or for Consultant's breach of this Agreement.

**B.** <u>Consultant's Standard of Care</u>. Subject to the other Agreement provisions, Consultant will provide Consultant's services under this Agreement with the same degree of care, skill, and prudence that would be customarily exercised in the Company's best interest.

#### C. <u>Confidential Information, Non-Disclosure Agreement and Work Product Ownership</u>.

(i) <u>Confidential Information</u>. Consultant acknowledges and agrees that during the Term of this Agreement, the Company shall grant Consultant otherwise prohibited access to its trade secrets and other Confidential Information (defined below) which is not known to the Company's competitors or within the Company's industry generally, which was developed by the Company over a long period of time and/or at its substantial expense, and which is of great competitive value to the Company. For purposes of this Agreement, "*Confidential Information*" includes all trade secrets and confidential and proprietary information of the Company, including, but not limited to, the following: software, technical, and business information relating to the Company's inventions and products (including product construction and product specifications), research, development, production processes, manufacturing and engineering processes, finances, services, know-how, technical data, policies, strategies, designs, formulas, programming standards, development tools or techniques, training manuals, marketing and sales plans and strategies, business plans, budgets, financial information and data, customer and client information, prices and pricing strategies, costs, customer and client lists and profiles, employee, customer and client nonpublic personal information, supplier lists, business records, audit processes, management methods and information, reports, recommendations and conclusions, information regarding the names, contact information, skills and compensation of employees and contractors of the Company, and other business information disclosed or made available to Consultant by the Company, either directly or indirectly, in writing, orally, or by drawings or observation.

#### (ii) <u>Non-Disclosure</u>.

(a) In exchange for the Company's agreement to provide Consultant with Confidential Information and to protect the Company's legitimate business interests, Consultant shall hold all Confidential Information in strict confidence. Consultant shall not, during the Term of this Agreement or at any time thereafter, disclose to anyone, or publish, use for any purpose, exploit, or allow or assist another person to use, disclose or exploit, except for the benefit of the Company, without prior written authorization, any Confidential Information or part thereof, except as permitted: (1) in the ordinary course of the Company's business or Consultant's work for the Company; or (2) by law. Consultant shall use all reasonable precautions to assure that all Confidential Information to: (1) call upon, solicit business from, attempt to conduct business with, conduct business with, interfere with or divert business away from any customer, client, vendor or supplier of the Company with whom or which the Company; and/or (2) recruit, solicit, hire or attempt to recruit, solicit, or hire, directly or by assisting others, any persons employed by or associated with the Company.

(b) Subject to Section IV.C.(ii)(c), Consultant agrees that Consultant shall not use or disclose any confidential or trade secret information belonging to any former employer or third party, and Contractor shall not bring onto the premises of the Company or onto any Company property any confidential or trade secret information belonging to any former employer or third party without such third parties' consent.

(c) During the Term of this Agreement, the Company will receive from third parties their confidential and/or proprietary information, subject to a duty on the Company's part to maintain the confidentiality of and to use such information only for certain limited purposes. Consultant agrees to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person or organization or to use it except as necessary in the course of Consultant's Consulting Services with the Company and in accordance with the Company's agreement with such third party.

(iii) <u>Work Product</u>.

(a) The work product from this Agreement may initially include, financial and business goals, timelines, tactics, budgets, forecasts, action items and other intellectual property with respect to the Company's business. Any and all of this intellectual property, or other intellectual property, which Consultant may make, conceive, discover, or develop, either solely or jointly with any other person or persons, at any time during the term of this Agreement in connection with the Consulting Services, whether at the request or upon the suggestion of the Company or otherwise, shall be the sole and exclusive property of the Company. Consultant hereby assigns to the Company, without further compensation, all rights, titles and interest in all such intellectual property rights in all countries of the world, including but not limited to all patent, copyright, trade secret and other proprietary rights therein.

(b) Consultant shall take all actions necessary so that the Company can prepare and present patent and copyright applications therefore, and can secure such copyright registrations or patents wherever possible, as well as reissue renewals, and extensions thereof, and can obtain the record title to such copyright or patents. Consultant shall not be entitled to any additional or special compensation or reimbursement regarding any such intellectual property. Consultant acknowledges that the Company from time to time may have agreements with other persons or entities which impose obligations or restrictions on the Company regarding inventions made during the course of work there under or regarding the confidential nature of such work. Consultant agrees to be bound by all such obligations and restrictions and to take all action necessary to discharge the obligations of the Company.

(c) In the event that Consultant uses or incorporates any works owned by Consultant, third party materials or other pre-existing materials not owned by Company (" *Pre-existing Materials* ") as part of the Consulting Services or related deliverables, Consultant hereby grants Company a perpetual, irrevocable, royalty free, world wide, transferable and sublicensable license to make, use, sell, import, reproduce, create derivative works of, distribute, publicly perform and display, and otherwise exploit such Pre-existing Materials.

(iv) <u>Return of Company Property</u>. Upon the termination of Consultant's Consulting Services under this Agreement for any reason or no reason, Consultant shall immediately return and deliver to the Company any and all Confidential Information, software, devices, data, reports, proposals, lists, correspondence, materials, equipment, computers, hard drives, papers, books, records, documents, memoranda, manuals, e-mail, electronic or magnetic recordings or data, including all copies thereof, books of account, drawings, prints, plans, and the like which belong to the Company or relate to the Company's business and which are in Consultant's possession, custody or control, whether prepared by Consultant or others. If at any time after termination of Consultant's Consulting Services under this Agreement, for any reason or no reason, Consultant determines that Consultant has any Confidential Information in Consultant's possession or control, Consultant shall immediately return to the Company all such Confidential Information in Consultant's possession or control, including all copies and portions thereof. Further, Consultant shall not retain any Confidential Information, data, information or documents belonging to the Company or any copies thereof (in electronic or hard copy format).

#### V. PERIOD OF AGREEMENT; TERMINATION

Period . This Agreement is effective from the Effective Date and shall continue until November 30, 2012 ("Term"). This A. Agreement governs all Consulting Services performed by Consultant for the Company during the Term of this Agreement. The Company or Consultant may terminate this Agreement for any reason or no reason, at any time, upon 15 days prior written notice to the other party. If this Agreement is terminated, either prior to or at the expiration of the Term, and the parties fail to execute a new agreement, all services will be discontinued as of the date of such termination and Consultant shall only be entitled to a pro rata portion of the monthly Consulting Fee for the month of termination based upon the actual number of days that have elapsed during the month that this Agreement is terminated; provided, however, that if the Company terminates this Agreement without "cause" (as defined below), Consultant shall be entitled to receive Consulting Fees for the full Term. For purposes of this Agreement, "cause" shall mean (i) conviction of Consultant of any felony involving moral turpitude or materially affecting the Company; (ii) any willful refusal by Consultant to carry out a reasonable directive of the Company's chief executive officer, which if remediable, is not remedied within five (5) business days (with appropriate reasonable adjustment if Consultant is at the time of notice away on vacation or otherwise out of the office) after delivery to Consultant of written notice from the Company specifying the details thereof; (iii) embezzlement of funds of the Company; (iv) any material breach of this Agreement by Consultant which if remediable, is not remedied within five (5) business days (with appropriate reasonable adjustment if Consultant is at the time of notice away on vacation or otherwise out of the office) after delivery to Consultant of written notice from the Company specifying the details thereof, or (v) any material breach of Consultant's fiduciary duties or duties of care to the Company (except for conduct taken in good faith), as determined in good faith by the Company's board of directors, which, if curable, remains uncured for five (5) business days after written notice thereof is given to Consultant.

**B.** <u>Survival</u>. The provisions set forth in Sections IV and VI.A shall survive termination or expiration of this Agreement. In addition, all provisions of this Agreement, which expressly continue to operate after the termination of this Agreement, shall survive the Agreement's termination or expiration.

#### VI. <u>RESIGNATION AND RELEASE</u>

A. <u>Resignation as President</u>. Concurrently with the execution of this Agreement, Consultant shall (i) resign as president of the Company and all other offices of the Company, effective immediately, and (ii) enter into that certain Separation Agreement and Release, of even date herewith, between InspireMD Ltd. and Occupational Safety & Health Ltd., Company No. 513308247, an entity controlled by Consultant, pursuant to which Consultant shall resign from all offices of InspireMD Ltd. and from the board of directors of InspireMD Ltd.

**B.** <u>Release</u>. In consideration for this Agreement and the Company's release of claims in VI.C., Consultant (individually and on behalf of his affiliates) knowingly and voluntarily releases and forever discharges, to the full extent permitted by law, the Company and any of its parents, predecessors, successors, assigns, subsidiaries, affiliates or related companies and organizations, and former or current officers, directors, shareholders, employees, attorneys, and agents, (collectively referred to throughout the remainder of this Agreement as the "*Company Parties*"), from any and all claims, controversies, allegations, matters, disputes, causes of action, losses, obligations, liabilities, damages, judgments, costs, expenses (including attorney's fees) of any kind whatsoever, known or unknown, asserted and unasserted, Consultant has or may have against the Company Parties as of the date of execution of this Agreement, including but not limited to those arising out of, or based upon:

(i) Consultant's hiring, employment or termination of employment with any Company Party, or arising out of any act committed or omitted during or after the existence of such employment relationship, including, but not limited to, any disputes regarding compensation, benefits or bonuses Consultant may or may not have received during employment with any Company Party including but not limited to any awards under the InspireMD, Inc. 2011 UMBRELLA Option Plan;

(ii) any foreign, federal, state or local law, rule or ordinance relating to any aspect of Consultant's relationship with any Company Party, including, but not limited to, discrimination, wages, hours worked, benefits, leave from employment due to illness or injury for Consultant or Consultant's family, claims for wrongful discharge, retaliation, fraud, breach of express or implied contract or implied covenant of good faith and fair dealing, and all other laws and regulations of any kind whatsoever. Furthermore, Consultant agrees and hereby relinquishes any right to re-employment with any Company Party;

(iii) any other foreign, federal, state or local civil or human rights law or any other local, state, federal or foreign law, regulation or ordinance of any kind;

(iv) any public policy, contract, tort, constitutional or common law claim, or claim for damages due to emotional distress or mental anguish; or

(v) any claim for costs, fees, or other expenses including attorneys' fees incurred in connection with any claim released;

provided however, that Consultant does not release or waive any claims that may arise solely by virtue of Consultant's position as a shareholder in the Company.

C. <u>Release by the Company</u>. In consideration for the Consultant's release of claims in VI.B., the Company knowingly and voluntarily releases and forever discharges, to the fullest extent permitted by law, the Consultant from any and all claims, controversies, allegations, matters, disputes, causes of action, losses, obligations, liabilities, damages, judgments, costs, expenses (including attorney's fees) of any kind whatsoever, known or unknown, asserted and unasserted, the Company has or may have against the Consultant as of the date of execution of this Agreement; provided however, that the Company does not release or waive any claims arising out of any illegal or fraudulent conduct by Consultant or that may arise solely by virtue of Consultant's position as a shareholder in the Company.

D. Later Discovered Facts. Consultant may later discover facts different from or in addition to those Consultant now knows or believes to be true regarding the matters released or described in this Agreement, and even so Consultant agrees that the releases and agreements contained in this Agreement remain effective in all respects notwithstanding any later discovery of any different or additional facts. Consultant assumes any and all risk of any mistake in connection with the true facts involved in the matters, disputes, or controversies released or described in this Agreement or with regard to any facts now unknown to Consultant relating thereto.

E. <u>Consultant Affirmations</u>. Consultant affirms that:

(i) Except for any amounts payable to Consultant under the Separation Agreement, Consultant has been paid and/or has received all leave (paid or unpaid), compensation, wages, bonuses, equity awards, meal and/or rest breaks, commissions, and/or benefits to which Consultant may be entitled and that no other leave (paid or unpaid), compensation, wages, bonuses, breaks, commissions and/or benefits are due to Consultant, except as specifically provided in this Agreement; and

(ii) Consultant is not aware of any claim he may have against or involving any Company Party, and is not aware of any violation of any law by any Company Party, including any securities laws.

#### VII. OTHER PROVISIONS

A. <u>Non-Disparagement</u>. Consultant agrees that the Company's goodwill and reputation are assets of great value to the Company which have been obtained and maintained through great costs, time and effort. Therefore, Consultant agrees that during the term of this Agreement and at all times thereafter, Consultant shall not in any way disparage, libel or defame the Company, its business or business practices, its products or services, or its affiliates, officers or directors. Consultant further agrees that during the term of this Agreement and at all times thereafter, Consultant shall not, directly or indirectly, communicate in any manner with any member of the press or media concerning the Company, its affiliates, current or former officers, directors, or Consultants except as permitted by law and/or Company policy.

**B.** <u>**Partial Invalidity**</u>. In the event any court of competent jurisdiction holds any provision of this Agreement to be invalid or unenforceable, such invalid or unenforceable portion(s) shall be limited or excluded from this Agreement to the minimum extent required, and the remaining provisions shall not be affected or invalidated and shall remain in full force and effect.

C. <u>Reformation</u>. Consultant agrees that in the event any of the covenants contained in this Agreement shall be held by any court to be effective in any particular area or jurisdiction only if said covenant is modified to limit its duration or scope, then the court shall have such authority to so reform the covenant and the parties hereto shall consider such covenant(s) and/or other provisions so as to comply with the order of any such court and, as to all other jurisdictions, the covenants contained herein shall remain in full force and effect as originally written.

**D.** <u>Entire Agreement</u>. This Agreement is the entire agreement between the parties with respect to the subject matter hereof, and fully supersedes any and all prior agreements, understandings, or representations between the parties, whether oral or written, pertaining to the subject matter of this Agreement. Consultant represents and acknowledges that in executing this Agreement, Consultant does not rely, and has not relied, upon any representation(s) by the Company or its agents except as expressly contained in this Agreement. Consultant agrees that Consultant has used Consultant's own judgment in executing this Agreement. This Agreement may not be amended unless it is in writing and signed by Consultant and the chief executive officer or chief financial officer of the Company.

E. <u>Controlling Law</u>. Any dispute in the meaning, effect, or validity of this Agreement and/or any dispute arising out of Consultant's relationship with the Company shall be resolved in accordance with the laws of the State of New York without regard to the conflict of laws provisions thereof. Venue of any litigation arising from this Agreement or Consultant's relationship with the Company shall be in a state district court of competent jurisdiction in New York County, New York, or the United States District Court for the Southern District of New York. Consultant consents to personal jurisdiction of the state district courts of New York and to the United States District Court for the Southern District of New York, and agrees that Consultant shall not challenge personal jurisdiction in such courts. Consultant waives any objection that Consultant may now or hereafter have to the venue or jurisdiction of any proceeding in such courts or that any such proceeding was brought in an inconvenient forum (and agrees not to plead or claim the same).

F. <u>Limitations on Assignment</u>. In entering into this Agreement, the Company is relying on the unique services of Consultant; services from another company or contractor will not be an acceptable substitute. Except as provided in this Agreement, Consultant may not assign this Agreement or any of the rights or obligations set forth in this Agreement without the explicit written consent of the Company. Any attempted assignment by Consultant in violation of this paragraph shall be void.

G. <u>Headings</u>. The headings contained in this Agreement are for reference purposes only and will not affect in any way the meaning or interpretation of this Agreement.

**H.** <u>Counterparts</u>. This Agreement and amendments to it will be in writing and may be executed in counterparts. Each counterpart will be deemed an original, but both counterparts together will constitute one and the same instrument.

I. <u>Ambiguities.</u> Any rule of construction to the effect that ambiguities shall be resolved against the drafting party shall not apply to the interpretation of this Agreement.

The signatures below indicate that the Parties have read, understand and will comply with this Agreement.

#### CONSULTANT:

Signature:	/s/ Asher Holzer
Printed Name:	Asher Holzer
Date:	June 1, 2012

#### INSPIREMD, INC.

Signature:	/s/ Ofir Paz
Name:	Ofir Paz

Title: CEO

#### **SEPARATIONAGREEMENTAND RELEASE**

This Separation Agreement and Release (the "Separation Agreement") is made this 1st day of June, 2012 by and between Inspire MD Ltd. (the "Company") and OSH-IL, The Israeli Society of Occupational Safety & Health Ltd., Company No. 513308247 ("Consultant").

WHEREAS, as of May 2005 the Key Person has been engaged by the Company, first as an employee and starting April 1 st, 2011 as its President and independent consultant through the Consultant, which is an Israeli corporation wholly controlled by the Key Person, under that certain Consultancy Agreement (the "Agreement"), a copy of which is attached as E x hibi t A hereto;

WHEREAS, Consultant informed the Company of its desire to cease providing the Services and resign from all of its and the Key Person's offices in the Company;

WHEREAS, due to the Consultant's aforesaid desire the parties have mutually agreed to terminate the Agreement effective as of June 1, 2012 (the "**Effective Date**") pursuant to the terms and conditions hereto;

WHEREAS, Consultant has agreed to release the Company from any and all claims, rights or demands arising from or related to the Agreement, the relations between the parties or the termination thereof;

NOW THEREFORE, in consideration of the mutual promises made herein, the Consultant and Company hereby agree as follows:

(Capitalized terms used herein and not otherwise defined shall have the respective meaning ascribed to them in the Agreement.)

- 1. <u>Termination of Agreement</u>.
- 1.1. The parties hereby terminate the Agreement and the engagement between them in mutual consent and effective as of the Effective Date.
- 1.2. As part of the termination of the Agreement (i) the Key Person hereby resigns from its offices as the President of the Company and member of its Board of Directors; and (ii) upon the Company's request, the Consultant and Key Person shall take all necessary actions in a timely manner to transfer all the information they possess on the Company to the Company's CEO or other person(s) designated by the Company's CEO, who will assume the Consultant's and Key Person's responsibilities.

- 2. <u>Release of Claims</u>.
- 2.1. By signing this Termination Agreement, the Consultant confirms that it has fully received from the Company all the payments and other rights to which it has been entitled from the inception of the Company and until June 1, 2012, including in connection with the Services and the employment of the Key Person by the Company as provided herein and particularly:
  - 2.1.1 Consultancy Fee under the Agreement and any previous salary for the period until June 1 st, 2012;
  - 2.1.2 Payment for unused absent days under Section 1.3 of the Agreement;
  - 2.1.3 Reimbursement of any costs or expenses incurred by the Consultant and/or the Key Person in connection with their engagement with the Company and its mother company;
  - 2.1.4 Any prior notice for the termination of the Agreement despite anything to the contrary in the Agreement and in any applicable law;

The Consultant and Key Person acknowledge that the payments of the funds and other rights as aforesaid have been in full satisfaction of any obligation of the Company, Inspire GmbH and InspireMD, Inc. (the "Affiliates") to Consultant and Key Person, including under the Agreement and the Company has no further obligation to the Consultant whatsoever.

2.2 Each of the Consultant and Key Person hereby irrevocable releases and forever discharges the Company, the Affiliates and its officers, directors, employees, managers, agents, investors, shareholders, representatives, predecessor and successor corporations, and assigns (the "Company's Release es") from, and agrees not to sue concerning, or, in any manner to institute, prosecute or pursue, any claim, complaint, charge, duty, obligation or cause of action relating to any matters of any kind, whether presently known or unknown, disclosed or undisclosed, liquidated or contingent, that Consultant or Key Person may possess against any of the Company's Releasees arising from any omissions, acts or facts that have occurred up until and including the date hereof including without limitation any and all claims or demands, directly or indirectly, relating to or arising out of the Agreement or Consultant's or Key Person's relationship with the Company, the termination of the Agreement and that relationship, including without limitation negligent, breach of contract, loss of profits and good will and the existence (which is denied) of labor relations between the parties as of April 1, 2011 until the Effective Date. The release included in this paragraph shall not apply to any cause the Key Person may have against InspireMD Inc. in his capacity as InspireMD Inc.'s shareholder.

Subject to any applicable law, the Company hereby and forever releases the Consultant and Key Person (the "**Consultant's Re l e as e e s**") from, and agrees not to sue concerning, or, in any manner to institute, prosecute or pursue, any claim, complaint, charge, duty, obligation or cause of action relating to any matters of any kind known to the Company on the date hereof, liquidated or contingent, that the Company may possess against any of the Consultant's Releasees arising from any omissions, acts or facts that have occurred up until and including the date hereof including without limitation any and all claims or demands, directly or indirectly, relating to or arising out of the Agreement or relationship between the parties, the termination of the Agreement and that relationship, including without limitation negligent, breach of contract, loss of profits and good will.

2.3. The parties acknowledge and agree that any breach of this Section 2 shall constitute a material breach of the Separation Agreement.

#### 3. <u>Survival of Obligations and Return of Company's Property</u>.

- 3.1. The termination of the Agreement shall not reveal the Consultant and Key Person from continue fulfilling their obligations under the Agreement which by their nature or as set forth in the Agreement are intended to survive the termination of the Agreement, including Sections 4 (Independent Contractor), 5 (Confidentiality), 6 (Creations and Inventions), 7 (Non-competition and Non-Solicitation), 8 (Miscellaneous) and Annex A (Undertaking) to the Agreement, all of which shall continue to bind the Consultant and Key Person without any change.
- 3.2. Consultant shall deliver to the Company on or before the Effective Date, and shall not keep in its possession, recreate or deliver to anyone else, any and all equipment, devices, records, data, notes, marketing materials, reports, e-mail messages, proposals, lists, correspondence, specifications, drawings, blueprints, sketches, materials, equipment, other documents or property, reproductions of any aforementioned items, or electronically stored or accessible copies or versions of such items, which were provided to the Consultant or Key Person by the Company or developed or obtained by the Consultant and Key Person in connection with their relation with the Company.

#### 4. <u>N on -D i sp a r a g e m e nt</u>

The parties mutually agree that the terms of the termination of the Agreement are amicable and mutually acceptable and each agree with the other that neither shall malign, defame, blame, or otherwise disparage the other, either publicly or privately regarding the past or future business or personal affairs of the other party, or any other officer, director or employee of such party.

#### 5. <u>General</u>

5.1. Save for that certain Consulting Agreement between the Key Person and InspireMD, Inc., dated of even date, this Separation Agreement supersedes and replaces all previous oral and written agreements or communications regarding the termination of the Agreement and the events leading thereto and associated therewith.

- 5.2. In the event that any provision or any portion of any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision or portion of provision, unless the absence of that provision or portion materially alters the rights and obligations of the signatories under this Separation Agreement.
- 5.3. This Separation Agreement may only be amended in writing signed by both parties.
- 5.4. This Separation Agreement shall be governed by and construed according to the laws of the State of Israel and any dispute arising under or in connection with this Separation Agreement shall be presented in and determined by the courts of Israel at Tel Aviv, exclusively, to whose sole jurisdiction the parties do hereby submit.
- 5.5. All notices, demands or other communications by either party to the other shall be in writing and shall be effective upon personal delivery or if sent by (i) mail seven days after deposited in the mail, first class postage, prepaid, Register or Certified; or (ii) by fax or email 1 business day (Sunday to Thursday) and all such notices given by mail, fax or email shall be sent and addressed as follows until such time as another address or fax number is given by notice pursuant to this provision.

If to Company:

Inspire Ltd. 4 Menorat Hamaor St., Tel Aviv Israel

Attention: Mr. Ofir Paz Fax No.: +972-3-6917692 Email:ofir@inspiremd.com If to Consultant / Key Person:

Bar Giura 8 St., Raanana Israel

Attention: Dr. Asher Holzer Email: asherh@netvision.net.il

[remainder of page intentionally left blank; signature page to follow]

IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as of the day and year first above written.

InspireMD Ltd.	OSH-IL, The Israeli Society of Occupational Safety & Health Ltd
By: <u>/s/ Ofir Paz</u>	By: /s/ Asher Holzer
Name: Ofir Paz	Name: Asher Holzer
Title: CEO	Title:

<u>Undertaking</u>

I the undersigned, Dr. Asher Holzer, hereby acknowledge that I read and fully understod the Termination Agreement to which this Undertaking is attached and agree that it shall bind me personally for all matter and purpose as if I was a party thereto.

/s/ Asher Holzer

#### Dr. Asher Holzer

Date: June 1 st., 2012

EXHIBIT A



#### FOR IMMEDIATE RELEASE

#### ASHER HOLZER RETIRES AS PRESIDENT OF INSPIREMD

Tel Aviv, Israel – June 5, 2012 – InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced that Asher Holzer, Ph.D., president and co-founder of the Company, is retiring as president of the Company. Dr. Holzer will remain a director of InspireMD and will also provide the Company with consulting services for a period of six months .

#### About MGuard<sup>TM</sup> Coronary Stent

MGuard<sup>TM</sup> combines a coronary stent merged with an embolic protection specifically designed for acute MI patients. The embolic protection is comprised of an ultra-thin polymer micron net that wraps the stent. The MGuard<sup>TM</sup> stent seeks to provide outstanding and lifelong embolic protection, without affecting deliverability. MGuard<sup>TM</sup> is CE Mark approved. Mesh-based protection is now recommended for use in the recent Guidelines of the Task force of Myocardial Revascularization of the European Society of Cardiology (ESC).

MGuard<sup>TM</sup> is currently being investigated in the multi-center international MASTER (MGuard<sup>TM</sup> for Acute ST Elevation Reperfusion) trial. This study has been designed to evaluate the MGuard<sup>TM</sup> stent compared to commercially-approved BMS or DES products in STEMI patients undergoing primary angioplasty. The trial is fully enrolled and preliminary top line results are expected in the third quarter of 2012. Plans for a registration study in the US are also at an advanced stage.

#### About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard  $^{TM}$ . InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is listed on the OTC BB under the ticker symbol "NSPR".

#### **Forward-looking Statements:**

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to

#### Page 2

secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (viii) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (ix) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers for certain product components, (xi) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at <u>www.sec.gov</u>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

#### **Investor Contact:**

Michael Rice Office Phone: (646) 597-6979 Email: mrice@lifesciadvisors.com

#### **Corporate Contact:**

Jonina Ohayon Marketing Director Email: jonina@inspire-md.com OTC BB: NSPR www.inspire-md.com

###